- Guillain-Barré Syndrome (GBS) is a rare but serious autoimmune neurological disorder where the body’s immune system mistakenly attacks the peripheral nerves. Growing recognition of the disease, coupled with improvements in diagnostic technologies and therapeutic interventions, is shaping the market's expansion, particularly in acute care settings.
- The rising demand for GBS treatment is primarily driven by increased incidence of viral and bacterial infections, such as Campylobacter jejuni, Zika virus, and COVID-19, which have been linked to triggering GBS. In addition, growing awareness, enhanced government support for rare diseases, and advancements in IVIG and plasma exchange therapies are fueling the market.
- North America dominates the Guillain-Barré Syndrome market, expected to hold the largest revenue share of over 38% in 2025, supported by robust healthcare infrastructure, high awareness levels, and increased investments in rare neurological disorder research. The U.S. leads the region, with strong adoption of advanced diagnostic tools such as nerve conduction studies and electromyography.
- Asia-Pacific is projected to be the fastest-growing region during the forecast period due to improving healthcare access, increased public health initiatives targeting neurological conditions, and a rising patient population. Countries such as India and China are witnessing increased diagnostic rates and evolving treatment accessibility.
- The Intravenous Immunoglobulin (IVIG) segment is expected to dominate the GBS therapeutics market, accounting for over 45% market share in 2025, attributed to its widespread use, faster onset of action, and inclusion in standard treatment protocols globally.
